Johnson & Johnson Innovation – JJDC contributed to Artizan Biosciences' series A round while Brii Biosciences invested through a licensing deal.
Artizan Biosciences, a US-based developer of treatments for inflammatory diseases, has raised $12m in funding from investors including Johnson & Johnson Innovation – JJDC, pharmaceutical group Johnson & Johnson’s corporate venturing unit.
The company closed its series A round but did not specify whether the $12m figure for the funding total pertains to the round or its history. It secured $3m in funding in 2016 and added $5m in March this year according to regulatory filings.
Spun out of Yale…
